Aptevo Therapeutics Augments Leadership Team
September 15 2016 - 10:30AM
Appoints Former GlaxoSmithKline Executive
Randy Maddux Senior Vice President,
Operations
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company
focused on developing novel oncology and hematology therapeutics,
today announced that Randy J. Maddux has joined the Company as
Senior Vice President, Operations, effective July 2016. Mr.
Maddux brings more than 30 years of biopharmaceutical operations
experience and has served in key roles supporting the licensure and
launch of several successful biopharmaceutical products, including,
Avonex®, Tysabri®, Benlysta® and Raxibacumab.
“We are delighted to welcome Randy to the
executive leadership team at Aptevo,” said Marvin White, President
and Chief Executive Officer. “Randy’s expertise in protein
therapeutic development and manufacturing is instrumental to our
vision of developing and advancing novel immuno-oncology
therapeutics based on our proprietary ADAPTIR™ bispecific antibody
technology platform. We view ‘manufacturability’ and
‘stability’ as critical success factors for bispecific antibody
platforms and consider these characteristics to be important
differentiators for the ADAPTIR™ platform. Randy’s knowledge
and leadership in the field will be invaluable as we develop and
advance our ADAPTIR™ product candidates to address important unmet
medical needs.”
In his new role at Aptevo, Mr. Maddux will work
closely with the research, clinical and regulatory organizations to
set strategic direction and provide operational support for the
development of novel bispecific antibody candidates derived from
Aptevo’s proprietary ADAPTIR™ platform. He will also provide
oversight and direction in support of the supply chain for the
Company’s four commercial products – IXINITY®, WINRHO®, HEPAGAM B®
and VARIZIG®.
Prior to joining Aptevo, Mr. Maddux served as
Vice President and Site Director at GlaxoSmithKline, where he led
the largest biopharmaceutical development and manufacturing site
within the GSK manufacturing network. Before that, Mr. Maddux
served as Vice President of Manufacturing Operations at Human
Genome Sciences, where he held executive responsibility for all
activities associated with the manufacture of therapeutic
proteins. Prior to joining Human Genome Sciences, Mr. Maddux
held various leadership roles in operations and quality at Biogen
and Glaxo. Mr. Maddux holds a M.B.A. from Duke University and
a B.S. from East Carolina University.
Mr. White continued, “We are also pleased to
announce the promotion of Jane Gross, Ph.D., to the position of
Senior Vice President and Chief Scientific Officer. Jane has
been instrumental in advancing the research and non-clinical
development efforts for our ADAPTIR™ platform under our predecessor
company, Emergent BioSolutions. Her expertise in immunology
and protein therapeutics is an important asset as we strive to
develop and advance novel immuno-oncology bispecific antibody
candidates based on our ADAPTIR™ platform.”
Dr. Gross has a Ph.D. in immunology and over
twenty-five years of experience in the discovery and development of
novel protein therapeutics in autoimmune, infectious disease and
oncology indications. Prior to joining Emergent, Dr. Gross served
as Vice President of Immunology Research at ZymoGenetics Inc.,
where she led efforts directed at the discovery and development of
therapeutics for the treatment of autoimmune disorders, infectious
diseases and cancer.
About Aptevo Therapeutics
Inc.Aptevo Therapeutics Inc. is a biotechnology company
focused on novel oncology and hematology therapeutics to
meaningfully improve patients’ lives. Our core technology is the
ADAPTIR™ (modular protein technology) platform. Aptevo has four
commercial products in the areas of hematology and infectious
diseases, as well as various investigational stage product
candidates in immuno-oncology.
Safe Harbor StatementThis press
release includes forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Any
statements, other than statements of historical fact, including,
without limitation, statements regarding the potential
opportunities and financial impact of the transaction, our
technology and related pipeline, collaboration and partnership
opportunities and any other statements containing the words
“believes,” “expects,” “anticipates,” “intends,” “plans,”
“forecasts,” “estimates,” “will” and similar expressions are
forward-looking statements. These forward-looking statements are
based on Aptevo’s current intentions, beliefs and expectations
regarding future events. Aptevo cannot guarantee that any
forward-looking statement will be accurate. Investors should
realize that if underlying assumptions prove inaccurate or unknown
risks or uncertainties materialize, actual results could differ
materially from Aptevo’s expectations. Investors are, therefore,
cautioned not to place undue reliance on any forward-looking
statement. Any forward-looking statement speaks only as of the date
of this press release, and, except as required by law, Aptevo does
not undertake to update any forward-looking statement to reflect
new information, events or circumstances.
There are a number of important factors that
could cause our actual results to differ materially from those
indicated by such forward-looking statements, including possible
negative effects on our business operations, assets or financial
results as a result of the separation; a deterioration in our
business or prospects; adverse developments in our customer-base or
markets; adverse developments in the U.S. or global capital
markets, credit markets or economies generally; and changes in
regulatory, social and political conditions. Additional risks and
factors that may affect results are set forth in our filings with
the Securities and Exchange Commission, including our Registration
Statement on Form 10, as amended. The foregoing sets forth many,
but not all, of the factors that could cause actual results to
differ from our expectations in any forward-looking
statement.
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
JurchisonS@apvo.com
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptevo Therapeutics (NASDAQ:APVO)
Historical Stock Chart
From Apr 2023 to Apr 2024